A Flounder Fish Peptide Shows Anti-Hypertensive Effects by Suppressing the Renin-Angiotensin-Aldosterone System and Endothelin-1

2021 ◽  
Vol 28 ◽  
Author(s):  
Mohamad Rahmdel ◽  
Sang Min Cho ◽  
You-Jin Jeon ◽  
Dae Ho Lee

Background: Many fishes have been known for their good nutritional effects especially in the cardiovascular aspect. Some specific fish peptides have anti-hypertensive effects. Objective: In the present study, we hypothesized that the hexapeptide (MEVFVP) from flounder fish muscle can be a potent antihypertensive peptide, therefore, decided to perform this experiment. Methods: The peptide MEVFVP from flounder fish muscle (40 mg/kg) and vehicle were administered per os to spontaneously hypertensive rats (SHRs) (SHR-M and SHR-C, respectively). Additionally, plasma MEVFVP was measured serially before and after its oral administration to Sprague Dawley rats. Results: Blood pressures (BPs), especially systolic BP, in SHR rats were decreased around 3-6 hours after MEVFVP administration. Compared with SHR-C rats, endothelin-1 (ET-1) mRNA expression in multiple tissues, and plasma levels of ET-1, angiotensin II, and aldosterone were lower in SHR-M rats, whereas the phosphorylation of AMP-activated protein kinase (AMPK) was increased in the kidney of SHR-M rats. The administered peptide was not detected in rat plasma, while ex vivo incubation of the peptide in rat plasma caused its rapid degradation within minutes. Conclusion: Our results show that the MEVFVP has an antihypertensive effect by regulating renin-angiotensin-aldosterone system, ET-1 and AMPK despite its limited bioavailability.

Heart Rhythm ◽  
2005 ◽  
Vol 2 (5) ◽  
pp. S240
Author(s):  
Frédéric Sacher ◽  
Agnes Georges ◽  
Prashantan Sanders ◽  
Jean-Benoit Corcuff ◽  
Philippe Schraub ◽  
...  

1978 ◽  
Vol 55 (6) ◽  
pp. 529-532 ◽  
Author(s):  
D. Weller ◽  
S. Azar ◽  
M. A. Johnson ◽  
M. Azar

1. We have correlated measurements of colloid osmotic pressure with protein concentrations and albumin/globulin ratios. Plasma from normal rats of different genetic strains was used. 2. The Landis and Pappenheimer equation does not accurately predict colloid osmotic pressure properties of the normal rat plasma used, which had an albumin/globulin ratio of 0.74. Over the range 2.2−12.2 g of protein/100 ml, the measured colloid osmotic pressures vary between −5% and +10% from the value predicted by the equation. 3. In Wistar-derived genetically hypertensive and normotensive rats, albumin/globulin ratios were higher than those in common Wistar rats. Owing to the presence of higher globulins, plasma proteins were higher in Wistar than spontaneously hypertensive and normotensive rats, and colloid osmotic pressure was identical in the three groups. 4. When common Sprague—Dawley rats were obtained from two different suppliers, their albumin/globulin ratios were found to be different. 5. As the difference in albumin/globulin ratio between human and rat plasma becomes more pronounced, predicting rat plasma colloid osmotic pressure from the Landis and Pappenheimer equation becomes less accurate. Environmental and/or genetic factors play a role in the albumin/globulin ratio found in normal healthy rats. 6. Therefore albumin/globulin ratios should be measured in each experimental situation. If the ratios are close to that of human plasma, the Landis and Pappenheimer equation can be used. If not, a new colloid osmotic pressure-protein expression should be derived. 7. Calculation of glomerular capillary pressures from directly measured colloid osmotic pressure values reduces error.


1982 ◽  
Vol 100 (4) ◽  
pp. 581-587 ◽  
Author(s):  
Bengt E. Karlberg ◽  
Anna-Maria Ottosson

Abstract. The incidence of arterial hypertension was evaluated in a partly retrospective study of patients with active acromegaly. Of 37 patients studied, 18 (48%) had hypertension, i.e. a supine blood pressure of > 160/95 mmHg. The type of hypertension was explored further by measuring plasma renin activity and, in some patients plasma aldosterone concentrations before and after stimulation (upright posture or furosemide 80 mg given orally). Urinary 24 h excretion of aldosterone was also determined. About half of the patients with hypertension but also a substantial part of normotensive acromegalics had inappropriately low plasma renin levels both during basal conditions and after stimulation. On the other hand urinary aldosterone excretion was either normal or (in 2 patients) slightly elevated. There was no other evidence of coexistent primary aldosteronism. Our results confirm previous reports of a high frequency of alterations in the renin-angiotensin-aldosterone system in acromegalic patients with growth hormone excess which in some instances may lead to an elevated blood pressure. The biochemical changes have many similarities to low renin essential hypertension. A volume factor may be operating in acromegalic patients with hypertension since in 10 patients treatment with the aldosterone antagonist, spironolactone, with doses between 50–200 mg daily lowered blood pressure to near normal levels. Thus, spironolactone seems to be a worthwhile alternative in the treatment of hypertensive acromegalics.


2011 ◽  
Vol 109 (suppl_1) ◽  
Author(s):  
Marko Poglitsch ◽  
Manfred Schuster ◽  
Hans Loibner

BACKGROUND: The Renin-Angiotensin-Aldosterone-System (RAAS) is an extensively studied peptide hormone system which is critically involved in the regulation of blood pressure and other important physiologic functions. Angiotensin-(1-10) which is liberated from angiotensinogen by kidney secreted Renin, is sequentially metabolized to different N- and C-terminal truncated fragments with partially described biologic activities. Beside Angiotensin II (Ang-(1-8)), various other angiotensin peptides including Ang-(1-7), Ang-(1-9), Ang-(2-8) and Ang-(3-8) are known to possess physiologic activity while Ang-(1-7) and more recently Ang-(1-9) were described to antagonize pathologic effects of Ang-(1-8) via vasodilation and antifibrotic action respectively. The role of Ang-(1-8) in hypertension converts enzymes participating in Ang-(1-8) generation to favorable targets for antihypertensive drugs. METHODS: Human blood was collected from healthy volunteers followed by ex-vivo incubation at 37°C in the presence of different inhibitors of angiotensin metabolism. Angiotensin concentrations were determined employing a novel sensitive LC-MS/MS based method, which allows the simultaneous quantification of a broad panel of angiotensin peptides in human plasma. RESULTS: The investigation of different angiotensin metabolism modifiers revealed agent specific patterns of angiotensin peptide levels reflecting the specificity of these inhibitors. Spiking experiments allowed the determination of turnover rates for distinct angiotensin conversion reactions surrounded by their physiological matrix. CONCLUSION: The measurement of blood concentrations of angiotensin peptides provides important information about the substrate specificities and activities of enzymes involved in their metabolism. This allows the identification of potential causes for pathologic conditions, facilitating a patient specific therapeutic modulation of the RAAS. The overall assessment of angiotensin peptide concentrations (Angiotensin-Peptide-Fingerprinting) represents a powerful tool to gain a more detailed understanding of blood pressure regulation, enabling the pharmacologic characterization of RAAS modifying agents in use and development.


Hypertension ◽  
2015 ◽  
Vol 65 (6) ◽  
pp. 1316-1323 ◽  
Author(s):  
Koen Verdonk ◽  
Langeza Saleh ◽  
Stephanie Lankhorst ◽  
J.E. Ilse Smilde ◽  
Manon M. van Ingen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document